Thanks, Josh, and thank all of you for joining us today for this important corporate update.
As Josh said, I'm Craig Parker, CEO of Surrozen.
is the today at Financial me Surrozen. with Chuck Chief Williams, Officer And
corporate updates R&D then be and We'll providing pipeline address today questions. will and
our our Slide filings, full Form discussion I'll be risk forward-looking a Please X. factors. our making XX-K for in annual XXXX consult particular, of report on statements. SEC
Slide X.
a this do the combine Wnt know, selectively mechanism biology physiologic for with repair to you We Surrozen innovator of of proprietary that in own the and our settings some diseases. preeminent and technologies techniques using body's through an in tissue broad regeneration platform in disease stimulate As is antibody engineering the range Wnt pathway, understanding pathway technologies. advanced proprietary of antibody specific tissue
tissue to this the and that Our therapeutic of disease-modifying benefit. antibodies The selective modulation distinguish vision to is regenerate approach ultimate potential is approach clinical in It's diseases. that the potential to targeted severe approach and applications our many Wnt develop and broad tissue our technologies. have extremely our promise design
range several to plays regulating tissue including tissue multivalent many to responses selectively severe see We biological role Wnt wide into and signaling pathway's therapeutics and signaling We've portends an Wnt have broad acute approaches in we regenerative benefit. a invented opportunities clinical antibody-based the modulating injury, to essential for myriad regenerate processes, of Wnt novel Wnt role believe advanced a to in physiologic and diseases. clinic. that the role for
clinical focused and disease to tissue key areas: long-term with our are inflammatory by donor limited significant X or alcoholic SZN-XXX Our candidate that with candidate hepatitis approach currently availability We're overcomes most SZN-XXXX. bowel regenerative severe limitation approaches medicine our a viability. of on
Boehringer our prioritization points key as corporate around with with for evaluation Ia an in elevations anticipated overview of disclosed pipeline our In efforts advancing lead and clinical initial XXXX. the had provide look you Phase the and we our programs, programs. time trials studies approach toward our inflection programs. our events clinical transaminase lines to we the provide partnered November, cash including in in commenced pipeline, adverse program research runway lead for Ingelheim, several of on expectations our We'll our observed in lead updates we'll updates, also Today, that and observed both
I Phase paused One Both of voluntarily pending of you are the enrollment. both Grade enzyme dose be trials. the currently update to transaminase for liver was to studies, I or ascending for clinical Phase further study on evaluation SZN-XXXX We're progress and open SZN-XXXX X to excited able SZN-XXX elevations. single
For SZN-XXX, we've enrolled and our we'll later provide information call. the first patient, more in
X. not Wnt why is If has decades pathway. to promising, many promiscuous are and it manufacturable. drug technical biology so are this themselves insoluble, Slide impediments. taken proteins Wnt There
platform recombinant is these native typical of a Surrozen's So possible. just and protein limitations. strategies not us technologies have helped strategy all overcome
are Our manufacturability. receptors. drug-like molecules that full as also linked tissue-specific They're have candidate highly to biospecific stability and properties desirable targeted solubility, such antibodies
what Wnt many Importantly, bodies our response, in peer-reviewed reports is and to injury. and proteins able scientific selective nature our communications. do maintain pathway nature work science, tissue record breakthrough a our are respond biology, our journals, chemical and so strong validated mimicking or in we're by cell publication in novelty way physiologic to of nature, high-impact to nature The including do either normal the of all antibodies a tissues,
modulate patent the received of modulation. SZN-XXXX families patent We establish key related program. in recently pathway over and have therapeutics use for filed and notices and a its dominant involving from our We for discoveries the Trademark or claims think the Surrozen United the our to We Office discoveries breadth position Patent to can allowance of application licensed us Wnt signaling. States assigned families and scientific related Wnt XX of the to to antibody related patent X
X. Slide
to lead have entered a treatment proprietary the of to development Boehringer quarter X clinic cornea on of the different lead programs focus led SZN-XXX gland. programs retinal technologies Ingelheim discovery licensing in that diseases candidate, in for Our pipeline for of XXXX and fourth lacrimal XXXX, the and X the
Our programs that a more few no high focus research ophthalmologic treatments, you indications of indications with on unmet about. tell including of available we'll or need group
grade programs and announcement plans. provide this XXXX regarding update and the to the on SZN-XXXX fourth lower transaminase an SZN-XXX in of and overview quarter to clinical seen our elevations, of SZN-XXXX. today efforts program. understand both you SZN-XXX transaminase we've excited with our date our program a advancing also of numerous the We're studies programs, an at of elevation Since in clinical mechanism in to provide We'll completed
For of patients excited disease completion liver study SZN-XXX, we're advanced we've really volunteers. following healthy the second in dosing to chronic phase in at X levels the dose of
dosing single a pursuing frequently to ascending minimal at antibodies study or I effect biological to Phase MABEL our lower progress level. will first-in-class we dose SZN-XXXX, strategy as referred anticipated applied For doses,
the with to Ingelheim, will the potential to with would look partner, candidate advance in the identify our a year-end, Surrozen. milestone that forward trigger development to a another FrizzledX by XXXX Boehringer opportunity development Additionally, candidate final to we payment in targeted collaboration
of our a key second milestones multiple half achieve prioritization that XXXX, cash catalysts. us anticipate will and in to restructuring runway result into allowing and the we Finally,
function multivalent activates in Slide signaling preclinical clinical ASGRX the a specifically molecule's and but that hepatocytes disease in developed liver, is X. We its compelling. align activating regeneration, severe resulting for in the to mimics activity and in of via R-spondin plan signaling concept importantly, liver and think clinical in specifically proliferation, SZN-XXX reduction -- disease We XXXX. pharmacology is Wnt pathologies support advance to SZN-XXX disease liver specific of is that into data treatment targeted trials data-driven our with rationale biological the the of hepatocyte binding. the Wnt improvement fibrosis. the antibody liver bispecific liver
which more detail. events we first dose mild-to-moderate mentioned, observed cohorts, describe in adverse As some X we'll in the
these subjects. planned our our impact severe did to next the in the hepatitis. Phase next steps ability and stage not in describe the advance into We'll alcoholic of Importantly, significant liver opportunity I program observations disease
Slide that mechanism. which to utilizes of hepatocytes. to X. is allows important activating ASGRX XXX cell-specific point platform the based Wnt XXXs out antibody well-characterized targeting hepatocyte-specific on activity our a for SZN-XXX target It's SWEETS to receptor,
to hepatocytes Our and effects protein well SWEETS technology. cell-specific animal activity technology occurring no studies level. of our of that confirmed dose regeneration and the to up with milligrams its per kilogram adverse mimics we Wnt a toxicology our naturally showed R-spondin's is the activity pathway R-spondin. on molecule described, We've the contribution XXX focused effects
AH to within by recent onset mortality of severe why the hepatitis of loss sufficient very XX% for The incidence with to the of of hospital, overcome to years. Alcoholic alcoholic that hepatitis and over explain severe and within regeneration increasing XX% of is coagulopathy severe think XX with of acute entity and right acute Short-term Surrozen. days patients due loss. die and hepatitis die me hepatocyte patients remains Let AH days for we clinical a high. use admission indication XX lack is the characterized in jaundice -- alcoholic molecule with disorder. is alcohol
treatment alcoholic year. hepatitis very X only than are half the therapeutic multiple capabilities. organ alcoholic transplants transplants There approved even has for in Corticosteroids decades to The no established without are with often AH rates success. on more potential contraindicated tested Liver about medical due for hepatitis. if agents of with not remain severe limited high drugs are patients. Hospitalization in donor And substantially and cost the the management but hepatitis severe in evolved are transplant last represent alcoholism. limitations denied are by and per alcoholic available, hospitalizations centers availability, XXX,XXX medical indicated
AH ICU. to are People with admitted severe the typically
population is need. high extremely an with an identifiable unmet this So
the approaches dollar of is a award million consumption think are of and population, over pandemic alcohol also during alignment by and during this disease alcoholic hospitalizations for the that need hepatitis. medical in XX% an this to pandemic increased reinforced our several increased We critical grant with the NIH of aware Surrozen mechanism We that the for pathophysiology dearth also by the program. novel
Importantly, is improved to survival. correlate hepatocyte known regeneration with
can are days is eligibility X objective of clinical scores score signs using and calculated to correlated response of a prognosis They we using practice with treatment, clinical Furthermore, Lille as early MELD the and are Both are laboratory for assess transplant. to of such The severity well-characterized and at surrogates Lille tools for common -- XX-day response and marker disease is utilize these assess benefit. tests bilirubin. highly like survival, survival. to that severity
seen in designation expect XX-day opportunity the there's such of disease grievous as a the for rapid diseases. survival believe and and need, We approvable potentially registration in medical an treatment trial. breakthrough endpoint as we severity pathway Because approval a unmet regulatory to favorable other be
rapidly fibrosis. section our These multiple proliferates in corporate We've demonstrating and X. liver in injury models from models future. Investors indications hepatitis liver reduction models fibrosis SZN-XXX mature Slide of that resulting hepatocytes spans translation indication improvements of our functional rodent found to to specific ultimately The in SZN-XXX published could data be to website. and of additional that injury efficacy can of alcoholic in a initial the provide the abstracts publications
excited first We're liver healthy single in I have patient cohorts and our Phase chronic to dose in we've with the XX. ascending X enrolled Slide completed study patients volunteers, disease. of
enrolled volunteers observed also TA mild-to-moderate kilogram. transaminitis X cohort treated that outcome one volunteers healthy per elevations milligrams We per we of Grade mildly in milligram a of the elevated a X second first dose of cohort spontaneously. the lower Following the healthy X in resolved case at X kilogram, at of
in chronic enrollment first I the enrolled the have Phase completion disease, SAD Following said, and as I Phase I healthy in SAD with opened patients in Cohort X patient. volunteers, of our we liver in
X cohort. sensitive enroll Patients with group We're per Cohort dosed the data X be subjects proceeding more We the be with tissue will preclinical SZN-XXX. doses may expect dose proliferation expand our hepatocyte option as kilogram. in effects X.X milligrams indicates of to that damaged to lower beneficial at per to an
single the Importantly, data disease ascending we by I in liver year-end from patients dose XXXX. chronic anticipate having Phase
study Assuming expected alcoholic acceptable of to be hepatitis proof-of-concept XXXX. available Phase safety, with data in Ib we second patients a anticipate half moving clinical in severe into XXXX, the in
look of SZN-XXX we believe SZN-XXX has target patients summary, ultimately, chronic severe a hepatitis. that understanding clinical In alcoholic and treatment We the liver of to of therapeutic with initial indication, initiate regulatory pathway. advancing with preclinical ideally and our that as with data disease and mechanism subjects potential our aligned we are development forward and well-defined SZN-XXX's
extensive based SZN-XXXX damaged the to intestinal critical Based healing a effect epithelium, showing barrier the colitis, agents SZN-XXXX leveraging disease. compelling developing on directly doses -- just complete X we SWAP of in and near mucosal designed contrast of biologics, In our XX. other have a of we're an bowel is function IBD. technology, models clinical plan of of to or or or opportunity severe Slide other using though, histologic suggests we reestablishment remission. experience biologic well-established rodent X healing to data inflammatory SZN-XXXX, development biology on drive and our preclinical in including from moderate X
laboratory of a function Grade serious Grade May the subjects. Phase Several transaminase in dosing X in clinically spontaneously healthy were subjects and total cohort with There dose In transaminase X other all SZN-XXXX resolved AST No subjects with elevations any including liver significant single-ascending treated other experienced study. during The and were increases adverse XX liver we and volunteer observed asymptomatic no elevations. no in subjects study. markers events changes XXXX, bilirubin X corresponding milligrams X ALT in ALT elevations commenced I elevations, X in at nor abnormalities.
give did opportunity November of in voluntary at ALT enrollment portion of to the Phase we a that a following I the a volunteer the X in grade an we an following elevation order clinical the dose in to the to announced study, require Although this analyze not data. -- observation pause protocol lower study halt healthy observation us
milligrams observed to We at have transaminase per GLP elevations toxicology in up any not doses or studies. kilogram other adversities or XXX pilot
significantly invested understand characterized as data with unexpected be TA the available efforts events. the at of were and nonclinical the events adverse could elevations. such, not in these observed the time mechanism of to We've So
healthy of we to better understanding the a additional data in the the portion dose combined data, weeks. in study, and next now SAD modified volunteers proceed dosing strategy, of Importantly, which allows I few with do the nonclinical clinical expect Phase us a to to
for of strategy no levels for dosing we're now colitis, rationale that's tested Such level dose. as antibodies on based with the multiple commonly is biological in TA minimum employed by dose active or MABEL effect elevation of studies or absence therapeutically models as initial for with a and dose a observations, a that, toxicities of doses said, informed SZN-XXXX pursuing strategy preclinically. observed agonistic of In as as Our indicators observed adverse SZN-XXXX was anticipated such well the activities first-in-human level. the light and I is effect any other NOAEL level a
XX. Slide
So inflammation reinforce for of need significant SZN-XXXX I immune-mediated the market. the probably frequently don't colitis. ulcerative this for Ulcerative need of in Initially, large a all unmet occurs colitis to but is you we're disease are that's remaining rectum, of inflammatory intestine developing chronic XX. between of extends to also the each million additional in areas affected. with colon. U.S. and the Nearly individuals XX incidence Peak proximately involve ages the the X associated and EU of
hospitalization. develop have UC least Some XX% patients of despite severe requiring And ulcerative acute will one therapy. at colitis activity episode with persistent disease medical
anti-inflammatory histologic course. in achieved XX remission better has following. low significant and remains rates therapies biologics induction, than need months current as to as in the Histologic Improved XX% clinical on patients anti-inflammatory market remission remission less biologics as efficacy, are for in been associated remission induce there of remission. a as development, a there clinical with at weeks, especially XX%. unmet can UC although low clinical of take Importantly, Rapid histologic the medical
Additional as first-line second -- and unmet mechanisms and therapies. as biologics need of action patients fail an additional subsequently many third-line anti-inflammatory fail
Slide XX.
barrier. and of that epithelial of directly of cells Wnt can circumstances cells, This rationale stem this ligands binds disrupted by address impaired differentiation wall, the leads in of the for epithelium component for and results inflammation in mimetic gut activity. as they the gut the epithelial Wnt barrier reduced immune a inflammatory these proliferation epithelial restoring out or IBD barrier binding in intestinal colon A produced is epithelial of further We've and and reduced the up what's bowel crypt disease. replacing allowing move to XXXX of So dysfunction. the pathophysiology cells the stromal the barrier. in normal that's inflammation shown in this major replacing an microbes gut damaged that are colon resulting crypt It inflammation. destroys preclinical SZN-XXXX in This to to disease the system, but exposure IBD.
Wnt activity favorably compares preclinical biologics also of signaling damage In demonstrated inflammatory XX. Slide studies, preclinical repairs we've and activity. models damaged We've the immunosuppressants. shown restores the that that disease in epithelium, colon reduces intestine, and this in cytokines approved XXXX colitis reduces to
of can preclinical this on abstracts data find website. You to some our related
Slide XX.
seen the rigorous for a several potential months, Over clinic in last established we've several identified the have hypotheses investigation plan. the transaminase science-based elevations we've and
have and data to experiments analyzing expertise in-house address Our specifically invaluable in questions. capabilities expeditiously designed proved conducting and additional the key available
our Let of activities, me conclusions. the some data and describe these
liver a systems. observed model specifically additional molecules human and systems, vivo to in established in experimental on We've in multiple not cells in We've employing human vivo in closely most vitro hepatocytes vitro order human physiology. that and our in toxic have effect do direct
effect multiple direct hepatocyte importantly, settings, vitro. seen any no that in our not And immune experimental no months. any killing undertaken few using we have we've cell ALT immune-mediated a activation, or observed not last death, have effects effect on studies over observed in no the We AST of
of that least hepatocyte-driven the hypothesis for partially their transaminase liver signaling Although understanding models different the light XXX the think transaminase effects. downstream of regeneration We'll the different applicability effects for supportive receptor employ in activation subsequent patterns elevations. pharmacokinetics similarities X systems to activity, to the of of XXXX responsible are for the additional Wnt and molecules between and We investigate shared. elevations at these of continue TA is Wnt and the mechanism pathway is
micrograms. effect be our a of at not liver-specific of XX would remind SZN-XXXX I'll of many next and liver to receptor this that you milligrams commencing expected X.XX be molecules We'll on either seems in healthy be or volunteers of administration. cohort based of affect a cells the targeting route to dosing also or dose
subsequent to and proceeding safety X least milligram. cohorts, doses Assuming to acceptable this we in at anticipate up
with of proof-of-concept half safety, second colitis ulcerative we expected in patients be in enrolling the XXXX. acceptable to anticipate available a proof-of-concept in Following study data XXXX,
XX. Slide
programs by with X stages We X have X candidate and Boehringer Surrozen optimization research partnered of or selection, owned wholly lead in Ingelheim. late
our mentioned, signaling role portends role found in a types tissues are plays Wnt physiologic responses regeneration broad validated in therapeutics body. central the a in cell and a vessels As acute diseases. tissue and through rodent this I We Wnt wide Wnt models role FrizzledX-mediated signaling collaborators for throughout believe own range of and and role retina has severe genetics, The been data blood of and publications. the in and human
in by a that targeted shown injury, leakage and the manifestations with fill retina This shown sign XXXX. we've retinopathies tufts. treatment injury, vascular stimulated unique and role October that reverse not collaboration In areas from including Boehringer a could of agreement could vascular characteristic us retinal and retinal to X in leakage We've an adequately that the models multiple of and mechanistic nonperfusion. different SZN-XXX neovascular areas FrizzledX addressing retinal SWAP, simultaneously a in SZN-XXX other led SZN-XXX in interest were partnership parties with vascularized multiple data and Ingelheim pathologic of
Slide XX.
We regenerating ultimately by is a by discomfort cell The a endothelial swelling caused corneal cornea. cells. program Fuchs endothelial excessive disease corneal loss also vision characterized loss research cell have loss of cause and need stages transplant progression endothelial and of understood, genetic well efficacy. corneal in Current unmet a has but not There disease. surgical the improve is or are for therapies and/or resection limited mitigate is a that therapies disease component. at late to of endothelial dystrophy significant
activate corneal signaling to the endothelial vision. and regenerate corneal reduce corneal is specifically disease treating cells for in strategy tissue, Our improve Wnt swelling
and to cells Wnt endothelium we've be human, activating used our therefore program development injury a in expressed primary are molecules the molecules. normal lead can model can for models in Wnt human molecule including to donors vitro. signaling step in corneal following: proliferation and of demonstrated measure therapeutic and Surrozen specific Fuchs' the specific and are And candidate. corneal vivo to endothelium. and that activation in and of improving effort, date the The reducing SWAP activating in a is select research that in through We've corneal designing SWAPs receptors have cryo targeting next our corneal established Wnt observe effect efficacious We thickness vitro corneal opacity. endothelial Frizzled of established both enhance a a in corneal In vivo optimize
atrophy results let that we're another potential Slide tell excited about pursuing severe eye ophthalmologic me to We're in with dry eye about. for other, cells. restore Severe you multiple a characterized SWAP models model program XX. dry lacrimal to secretion. is in a treatment Well, technology. gland the which our that activating injury, by called gland Wnt producing inflammation-driven the insufficient lacrimal in fluid production tear We've the of in tear regeneration objective ligation the The in in tear using approach gland necrosis the stimulate regeneration. lacrimal One cells tear-producing established glands production step Intraleukin-X acinar and is in first important to duct the regenerate and with the the injury the gland. mechanistic eye is tear alpha An rodents, reduced. restoring to the is of promote producing cells
a SWAP the acinar cells. increase in We've injection weight shown that a a of the demonstrable gland molecule of and an these proliferation in lacrimal of single results
model, signaling model, SWAP the activation X a significant model proliferation secretion. molecule agents phenol SWAP actually of in increase leads of that in gland. effect statistically tear thread. tear tear cells and red is clear gland of target with activate in injury, SWAP in increase model which X. we've X, induced IL-Xa for with eye, secretion treatment tear days number of an restores a trials signaling that In Similarly, a this molecules Wnt and duct measuring level clinical production cells. we've in production having a tissue, that the the the as through lacrimal method acinar the we're increasing to at the the this in shown for there's of in ligation dry used shown The injury molecules cellular Wnt So at of same In
Next for lead a the finalize optimize molecule to and program step development. is for
of local would development Both of We liabilities. in a to one our expect corporate affected to therefore, collaboration potentially forward at liver least with have involve be not into administration tissue programs and partner. exposure the any these move expected antibodies in to potential XXXX,
Chuck. and to turn Slide to over I'm XX, slide the going
